INNOVIVA, INC. Long-Term Debt, Maturity, Year Five
INNOVIVA, INC. (INVA) had Long-Term Debt, Maturity, Year Five of $261.00 million as of 2023-12-31, per its 10-K/A filed 2024-03-05.
Discontinued › Notes › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2024-03-05
- 2023-12-31: Long-Term Debt, Maturity, Year Five $261.00M.
- 2022-12-31: Long-Term Debt, Maturity, Year Five $0.00.
- 2020-12-31: Long-Term Debt, Maturity, Year Five $0.00.
- 2020-06-30: Long-Term Debt, Maturity, Year Five $0.00.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2023-12-31 | $261.00M 10-K/A · filed 2024-03-05 |
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-29 |
| 2020-03-31 | $0.00 10-Q · filed 2020-04-29 |
| 2019-12-31 | $0.00 10-K · filed 2020-02-19 |
| 2019-09-30 | $240.98M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $240.98M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $240.98M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $240.98M 10-K · filed 2019-02-19 |
| 2018-09-30 | $13.75M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $123.75M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $123.75M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $143.75M 10-K · filed 2018-02-23 |
| 2017-09-30 | $25.00M 10-Q · filed 2017-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |